Actemra - Consumer Justice Foundation

Actemra

Start Claim Now

Possible side effects of the blockbuster rheumatoid arthritis drug Actemra include heart attack, interstitial lung disease, pancreatitis and wrongful death.

The U.S. Food and Drug Administration (FDA) has received thousands of reports from patients who suffered serious adverse events associated with the rheumatoid arthritis drug Actemra, and hundreds of people have died while taking the prescription medication in recent years, yet there are no warnings about these risks on the Actemra drug label. If you believe you or someone you love has been harmed by alleged side effects of Actemra, like heart attack, interstitial lung disease or pancreatitis, contact an experienced product liability lawyer as soon as possible to discuss the possibility of filing an Actemra injury lawsuit against Roche Holding AG.

Actemra Alternatives for Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a painful autoimmune disease that causes swelling and stiffness in joints, and while it typically begins in middle age, it can affect children and young adults as well. A popular treatment for rheumatoid arthritis is Actemra, a prescription medication that, unlike many other arthritis drugs, doesn’t carry warnings about an increased risk of heart attacks and strokes. However, post-marketing reports suggest that Actemra may come with a risk of cardiovascular side effects and other health problems that is as high or higher than similar rheumatoid arthritis drugs. Patients with rheumatoid arthritis who want to avoid such risks may want to consider alternative treatments and therapies that can relieve RA flare-ups and help slow the progression of the disease, such as:

  • Using a heating pad to relax tense muscles and soothe painful joints
  • Stretching to improve flexibility and physical function
  • Undergoing physical therapy to restore muscle strength and function
  • Undergoing reconstructive surgery to repair damage to tendons and relieve pressure on nerves
  • Undergoing joint replacement surgery to replace a defective or damaged joint with a new one
  • Getting regular exercise and a good night’s sleep
  • Using topical ointments for temporary relief of minor joint pain
  • Taking fish oil supplements to help reduce joint pain and stiffness
  • Applying an ice pack to inflamed joints to ease swelling

FDA, Actemra and Side Effects

2008 – At a meeting of FDA scientific advisors debating whether to approve Actemra, a rheumatologist at Boston University voices concerns about the potential for the arthritis drug to cause serious heart problems in users. They ultimately recommend approval of Actemra, with the condition that Roche would sponsor multiyear studies to look for unseen problems and cardiovascular side effects. None of these warnings are added to the drug label.

March 2009 – A report identifies 15 deaths and more than 200 severe side effects in patients in Japan taking Actemra.

2011Warnings about “fatal anaphylaxis” are added to the Actemra label, following at least two patient deaths.

2012 – Roche petitions the FDA to expand Actemra’s indications for use among patients who have failed to get relief from only one other rheumatoid arthritis drug, instead of two.

September 2012 – The FDA identifies 258 cases of pancreatitis and 185 cases of interstitial lung disease among Actemra users in clinical trials, epidemiological data and the agency’s own adverse event reporting system.

2013 – The FDA launches a full safety review of Actemra, identifying about 3,500 adverse event reports submitted to the agency as of August 2012, including 118 deaths, 42 of which are linked to cardiac arrest or myocardial infarction.

2014 – A 62-year-old German woman suffers a heart attack and Roche “assessed fatal myocardial infarction as related to (Actemra).”

January 2016 – A report by the Government Accountability Office warns that the FDA is approving too many medications through its 510(k) fast-track approval process, and then failing to adequately monitor them once they enter the market.

May 2017 – Actemra’s approval is expanded by the FDA to include treatment for a form of vasculitis called giant cell arteritis, based on a one-year study that involved just 149 patients who took the medication.

June 2017 – STATNews.com releases a scathing report highlighting about 13,500 reports of side effects involving an Actemra infusion or injection submitted to the FDA between 2010 and 2016, including at least 1,128 deaths.

Actemra Side Effect Studies

October 2016 – In a study comparing Actemra to Enbrel, which carries warnings about the potential risk of cardiovascular disease and heart failure, researchers find a 1.5-times increased risk of stroke and heart failure among Actemra users.

May 2017 – A study published in the Journal of the American Medical Association warns that one-third of all drugs approved by the FDA are later required to update their labels or are recalled from the market due to adverse side effects.

June 2017 – In a study published in the journal Arthritis & Rheumatology, researchers find nearly identical rates of strokes and heart attacks among patients taking Actemra and other rheumatoid arthritis medications.

Why We Think Roche Should Be Held Liable for Actemra Side Effects

When Actemra first entered the market, there were several other rheumatoid arthritis drugs already available, including Humira, Remicade and Enbrel, and while these medications carried strong warnings about their potential for causing serious cardiovascular side effects in users, the Actemra label contained no such warning. As a result of Roche’s failure to include adequate warnings about the possible side effects of Actemra, patients and healthcare professionals were led to believe that the drug was safer than the available alternatives, which recent research has proven otherwise. While hundreds of people have died from alleged Actemra side effects, and thousands of others have suffered devastating complications while taking Actemra, Roche has gotten rich off its blockbuster arthritis drug, which generated $1.7 billion in sales in 2016 alone. Future Actemra lawsuits brought against Roche in will likely accuse the company of the following:

  • Designing and manufacturing a defective medication
  • Failing to adequately research the long-term health risks associated with Actemra
  • Knowing about the potential for Actemra to pose a risk of heart attack and other serious side effects
  • Concealing information about these potential side effects from consumers and the medical community
  • Failing to issue an Actemra recall or update warnings on the drug label
  • Overstating the benefits of Actemra treatment and downplaying the drug’s health risks

What should you do? If you have suffered a heart attack, stroke or another serious side effect, you should contact a lawyer as soon as possible to discuss filing an Actemra injury lawsuit.

The rheumatoid arthritis drug Actemra has been linked to a higher-than-expected number of serious and potentially life-threatening side effects when compared to other arthritis medications, many of which carry warnings on their labels about adverse events like heart attack, stroke, lung disease, heart failure and wrongful death. If you or a loved one took Actemra and you have since suffered a serious medical complication, our consumer advocates at the Consumer Justice Foundation can help. We are dedicated to protecting the rights of consumers harmed by defective pharmaceutical drugs, and can help put you in touch with an attorney who has experience handling Actemra injury claims.

Start Claim Now
Do you deserve compensation?

An attorney will review your situation for FREE and help you found out what really went wrong.

How Can We Reach You?

Please Explain Your Situation

By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.
×